Dynamic change of circulating innate and adaptive lymphocytes subtypes during a cascade of gastric lesions
Dynamic change of circulating innate and adaptive lymphocytes subtypes during a cascade of gastric lesions
复制标题
胃部病变级联过程中循环先天性和适应性淋巴细胞亚型的动态变化
DOI：
10.1002/jlb.5ma0422-505r
复制
发表时间：
2022-06-03
影响因子：
5.5
通讯作者：
Ding, Shigang
中科院分区：
文献类型：
--
作者：
Fu, Weiwei;Wang, Wenyan;Ding, Shigang
根据Correa模型，胃粘膜型胃癌（GC）发生之前存在癌前病变，包括慢性胃炎、肠上皮化生和异型增生。但在此过程中天然免疫和获得性免疫应答的动态变化尚未得到全面研究。在这项研究中，我们进行了全面的和轨迹分析循环先天淋巴细胞（ILC）和适应性Th淋巴细胞亚型的患者跨越级联胃病变。在胃炎、癌前病变和胃癌组中发现循环ILC2频率增加，而与癌前病变组相比，在胃癌组中检测到进一步降低的ILC2。ILC3s在胃炎、癌前病变和胃癌分期中的表达均高于健康对照组。此外，上调的T滤泡辅助（Tfh）细胞的比例检测胃炎和癌前病变。总之，通过分析循环ILC和Th细胞的频率和关键细胞因子的产生或免疫球蛋白水平，我们证明了ILC3和Tfh在胃疾病中的潜在参与。这些发现将有助于理解胃癌及其癌前病变的免疫学机制，并为预防胃癌的发生发展提供潜在的治疗靶点。
According to the Correa model, the intestinal-type gastric cancer (GC) is preceded by premalignant lesions, including chronic gastritis, intestinal metaplasia and dysplasia. However, the dynamic change of innate and adaptive immune response during this process has not been studied comprehensively. In this study, we performed a comprehensive and trajectory analysis of circulating innate lymphoid cells (ILCs) and adaptive Th lymphocytes subtypes in patients spanning a cascade of gastric lesions. Increased circulating ILC2s frequency was found in the gastritis, premalignant stage and GC group, whereas further decreased ILC2s were detected in the GC group compared with the premalignant group. Moreover, ILC3s level was higher in both gastritis, premalignant lesion and GC stage, compared with healthy controls. Furthermore, up-regulated T follicular helper (Tfh) cell proportions were detected in the gastritis and premalignant process. In conclusion, by analyzing the circulating ILCs and Th cells frequency and the key cytokine production or immunoglobulin level, we demonstrated the potential involvement of ILC3 and Tfh in the gastric diseases. These findings will help to understand the immunologic mechanisms in both GC and the premalignant process and contribute to serve potential therapeutic targets to prevent the GC development.